Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HG153
- Development stage
- Preclinical
- Lead developer
- HitGen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HG153 is a small molecule inhibitor of the menin-MLL protein-protein interaction, developed by HitGen and Yunzhong Pharmaceutical. It targets the interaction between menin and the N-terminus of MLL (KMT2A), which is essential for the maintenance of HOXA9 and MEIS1 gene expression in certain leukemias. By disrupting this complex, HG153 induces cell cycle arrest, differentiation, and apoptosis in MLL-rearranged and NPM1-mutant leukemia cells. The drug is formulated as an oral tablet and is currently in preclinical development for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) harboring these specific genetic alterations.
02
Targets
KMT2A
Beyond the preview
Go deeper on HG153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HG153.